journal
MENU ▼
Read by QxMD icon Read
search

Journal of Nuclear Medicine: Official Publication, Society of Nuclear Medicine

journal
https://www.readbyqxmd.com/read/29146698/characterization-of-site-specifically-conjugated-monomethyl-auristatin-e-and-duocarmycin-based-anti-psma-antibody-drug-conjugates-for-treatment-of-psma-expressing-tumors
#1
Susanne Lütje, Danny Gerrits, Janneke D Molkenboer-Kuenen, Ken Herrmann, Giulio Fracasso, Marco Colombatti, Otto C Boerman, Sandra Heskamp
Rationale: Prostate cancer (PCa) is the most common cancer in men worldwide. In general, PCa responds poorly to chemotherapy. Therefore, antibody-drug conjugates (ADCs) have been developed to specifically deliver highly cytotoxic drugs to the tumor. As the prostate-specific membrane antigen (PSMA) is overexpressed in PCa, it represents a promising target for ADC-based therapies. The aim of this study was to evaluate the therapeutic efficacy of site-specifically conjugated duocarmycin- and monomethyl auristatin E (MMAE)-based anti-PSMA ADCs with drug-antibody ratios (DARs) of 2 and 4...
November 16, 2017: Journal of Nuclear Medicine: Official Publication, Society of Nuclear Medicine
https://www.readbyqxmd.com/read/29146697/challenging-nuclear-cardiology-research-stimulating-discovery-validation-and-clinical-relevance
#2
Vasken Dilsizian
No abstract text is available yet for this article.
November 16, 2017: Journal of Nuclear Medicine: Official Publication, Society of Nuclear Medicine
https://www.readbyqxmd.com/read/29146696/optimizing-strategies-for-immune-checkpoint-imaging-with-immumo-pet-in-preclinical-study
#3
Jiale Chen, Ning Wang, Xinyu Yang, Yuan Li
No abstract text is available yet for this article.
November 16, 2017: Journal of Nuclear Medicine: Official Publication, Society of Nuclear Medicine
https://www.readbyqxmd.com/read/29146695/first-in-human-her2-targeted-imaging-using-89-zr-pertuzumab-pet-ct-dosimetry-and-clinical-application-in-patients-with-breast-cancer
#4
Gary A Ulaner, Serge K Lyashchenko, Christopher Riedl, Shutian Ruan, Pat B Zanzonico, Diana Lake, Komal Jhaveri, Brian Zeglis, Jason S Lewis, Joseph A O'Donoghue
In this first-in-human study, we evaluate the safety and dosimetry of (89)Zr-pertuzumab PET/CT for HER2-targeted imaging in patients with HER2-postive breast cancer. Materials and Methods: Patients with HER2-positive breast cancer and evidence of distant metastases were enrolled in an Institutional Review Board (IRB)-approved prospective clinical trial. Pertuzumab was conjugated with deferoxamine and radiolabeled with (89)Zr. Patients underwent (89)Zr-pertuzumab PET/CT with 74 MBq of (89)Zr-pertuzumab in a total antibody mass of 20-50 mg of pertuzumab...
November 16, 2017: Journal of Nuclear Medicine: Official Publication, Society of Nuclear Medicine
https://www.readbyqxmd.com/read/29146694/spatiotemporal-distribution-of-%C3%AE-amyloid-in-alzheimer-s-disease-results-from-heterogeneous-regional-carrying-capacities
#5
Alex Whittington, David J Sharp, Roger N Gunn
β-amyloid (Aβ) accumulation in the brain is one of two pathological hallmarks of Alzheimer's Disease (AD) and its spatial distribution has been studied extensively ex vivo. We apply mathematical modelling to Aβ in vivo PET imaging data in order to investigate competing theories of Aβ spread in AD. Our results provide evidence that Aβ accumulation starts in all brain regions simultaneously and that its spatiotemporal distribution is a result of heterogeneous regional carrying capacities (regional maximum possible concentration of Aβ) for the aggregated protein rather than longer term spreading from seed regions...
November 16, 2017: Journal of Nuclear Medicine: Official Publication, Society of Nuclear Medicine
https://www.readbyqxmd.com/read/29146693/reply-advantages-and-limits-of-targeted-radionuclide-therapy-with-somatostatin-antagonists
#6
Guillaume Nicolas, Damian Wild, Melpomeni Fani
No abstract text is available yet for this article.
November 16, 2017: Journal of Nuclear Medicine: Official Publication, Society of Nuclear Medicine
https://www.readbyqxmd.com/read/29146692/prediction-of-90-y-radioembolization-outcome-from-pre-therapeutic-factors-with-random-survival-forests
#7
Michael Ingrisch, Franziska Schöppe, Karolin Johanna Paprottka, Matthias Fabritius, Frederik F Strobl, Enrico de Toni, Harun Ilhan, Andrei Todica, Marlies Michl, Philipp Paprottka
To predict outcome of (90)Y radioembolization (RE) in patients with intrahepatic tumors from pre-therapeutic baseline parameters and to identify predictive variables using a machine-learning approach based on random survival forests (RSF). Materials and Methods: In this retrospective study, 366 patients with primary (n = 92) or secondary (n = 274) liver tumors who had received (90)Y radioembolization were analyzed. A random survival forest was trained to predict individual risk from baseline values of cholinesterase (CHE), bilirubin, type of primary tumor, age at radioembolization, hepatic tumor burden, presence of extrahepatic disease (EHD) and sex...
November 16, 2017: Journal of Nuclear Medicine: Official Publication, Society of Nuclear Medicine
https://www.readbyqxmd.com/read/29123015/the-irony-of-pet-tau-probe-specificity
#8
Jorge R Barrio
No abstract text is available yet for this article.
November 9, 2017: Journal of Nuclear Medicine: Official Publication, Society of Nuclear Medicine
https://www.readbyqxmd.com/read/29123014/positron-emission-tomography-using-a-grpr-antagonist-68-ga-rm26-in-healthy-volunteers-and-prostate-cancer-patients
#9
Jingjing Zhang, Gang Niu, Xingrong Fan, Lixin Lang, Guozhu Hou, Libo Chen, Huanwen Wu, Zhaohui Zhu, Fang Li, Xiaoyuan Chen
This study was designed to study the safety, biodistribution, radiation dosimetry of a gastrin-releasing peptide receptor (GRPR) antagonist positron emission tomography (PET) tracer (68)Ga-RM26, to assess its clinical diagnostic value in prostate cancer patients, and to perform a direct comparison between GRPR antagonist (68)Ga-RM26 and agonist (68)Ga-BBN. Methods: Five healthy volunteers were enrolled to validate the safety of (68)Ga-RM26 and calculate dosimetry. A total of 28 patients with prostate cancer (17 newly diagnosed and 11 post therapy) were recruited with written informed consent...
November 9, 2017: Journal of Nuclear Medicine: Official Publication, Society of Nuclear Medicine
https://www.readbyqxmd.com/read/29123013/-68-ga-psma-pet-ct-mapping-of-prostate-cancer-biochemical-recurrence-following-radical-prostatectomy-in-270-patients-with-psa-1-0ng-ml-impact-on-salvage-radiotherapy-planning
#10
Jérémie Calais, Johannes Czernin, Minsong Cao, Amar U Kishan, John V Hegde, Narek Shaverdian, Kiri A Sandler, Fang-I Chu, Chris R King, Michael L Steinberg, Isabel Rausher, Nina-Sophie Schmidt-Hegemann, Thorsten Poeppel, Philipp Hetkamp, Francesco Ceci, Ken Herrmann, Wolfgang P Fendler, Matthias Eiber, Nicholas G Nickols
Background: Target volume delineations for prostate cancer (PCa) salvage radiotherapy (SRT) after radical prostatectomy are usually drawn in the absence of visibly recurrent disease. Gallium-68 Prostate Specific Membrane Antigen Positron Emission Tomography/Computed Tomography ((68)Ga-PSMA-11 PET/CT) detects recurrent PCa with sensitivity superior to standard of care imaging at serum prostate specific antigen (PSA) values low enough to impact target volume delineations for routine SRT. OBJECTIVE: To i) map the recurrence pattern of PCa early biochemical recurrence (BCR) after radical prostatectomy with (68)Ga-PSMA-11 PET/CT in patients with serum PSA levels <1 ng/ml, ii) determine how often consensus clinical target volumes (CTV) based on the Radiation Therapy Oncology Group (RTOG) guidelines cover (68)Ga-PSMA-11 PET/CT-defined disease, and iii) assess the potential impact of (68)Ga-PSMA-11 PET/CT on SRT...
November 9, 2017: Journal of Nuclear Medicine: Official Publication, Society of Nuclear Medicine
https://www.readbyqxmd.com/read/29123012/prostate-cancer-molecular-imaging-standardized-evaluation-promise-proposed-mitnm-classification-for-the-interpretation-of-psma-ligand-pet-ct
#11
Matthias Eiber, Ken Herrmann, Jeremie Calais, Boris Hadaschihk, Frederik L Giesel, Markus Hartenbach, Thomas Hope, Robert Reiter, Tobias Maurer, Wolfgang A Weber, Wolfgang P Fendler
Prostate-specific membrane antigen (PSMA)-ligand positron emission tomography (PET)-imaging provides unprecedented accuracy for whole body staging of prostate cancer. As PSMA-ligand PET/computed tomography (CT) is increasingly adopted in clinical trials and routine practice worldwide, a unified language for image reporting is urgently needed. We propose a molecular imaging tumor, node and metastasis system (miTNM Version 1.0) as standardized reporting framework for PSMA-ligand PET/CT or PET/magnetic resonance imaging (MRI)...
November 9, 2017: Journal of Nuclear Medicine: Official Publication, Society of Nuclear Medicine
https://www.readbyqxmd.com/read/29123011/imaging-synaptic-density-a-different-look-at-neurological-diseases
#12
Eugenii Ilan A Rabiner
No abstract text is available yet for this article.
November 9, 2017: Journal of Nuclear Medicine: Official Publication, Society of Nuclear Medicine
https://www.readbyqxmd.com/read/29123010/reply-psma-ligands-for-imaging-prostate-cancer-alternative-labeling-by-complex-formation-with-al-18-f
#13
Frederik L Giesel, Klaus Kopka
No abstract text is available yet for this article.
November 9, 2017: Journal of Nuclear Medicine: Official Publication, Society of Nuclear Medicine
https://www.readbyqxmd.com/read/29123009/new-challenges-in-nuclear-endocrinology
#14
David Taieb, Rodney Hicks, Karel Pacak
No abstract text is available yet for this article.
November 9, 2017: Journal of Nuclear Medicine: Official Publication, Society of Nuclear Medicine
https://www.readbyqxmd.com/read/29123008/reproducibility-of-mr-based-attenuation-maps-in-pet-mri-and-the-impact-on-pet-quantification-in-lung-cancer
#15
Anders Olin, Claes N Ladefoged, Natasha H Langer, Sune H Keller, Johan O Löfgren, Adam E Hansen, Andreas Kjær, Seppo W Langer, Barbara M Fischer, Flemming L Andersen
AIM: Quantitative positron emission tomography/magnetic resonance imaging (PET/MRI) is dependent upon reliable and reproducible MR-based attenuation correction (MR-AC). In this study we evaluated the quality of current vendor-provided thoracic MR-AC maps, and further investigated the reproducibility of these in terms of their impact on fluorodeoxyglucose (FDG)-PET quantification in patients with non-small cell lung cancer (NSCLC). MATERIAL AND METHODS: Eleven patients with inoperable NSCLC underwent two to five thoracic PET/MRI scan-rescan examinations within 22 days...
November 9, 2017: Journal of Nuclear Medicine: Official Publication, Society of Nuclear Medicine
https://www.readbyqxmd.com/read/29097410/f-18-fdg-pet-ct-in-erdheim-chester-disease-imaging-findings-and-potential-braf-mutation-biomarker
#16
Jason Young, Geoffrey Bates Johnson, Robert Charles Murphy, Ronald S Go, Stephen M Broski
This study's purpose was to evaluate F-18 fluorodeoxyglucose positron emission tomography - computed tomography (FDG PET-CT) in the diagnosis, management and treatment of Erdheim-Chester disease (ECD). Methods: Our institutional database (2007-2017) was retrospectively reviewed for patients with pathologically-proven ECD. A chart review recorded demographics, clinical information and five categories of clinical impact. Two radiologists in consensus interpreted the images. Imaging findings were correlated with clinical data...
November 2, 2017: Journal of Nuclear Medicine: Official Publication, Society of Nuclear Medicine
https://www.readbyqxmd.com/read/29097409/optimizing-image-quantification-for-lu-177-spect-ct-based-on-a-3d-printed-2-compartment-kidney-phantom
#17
Johannes Tran-Gia, Michael Lassmann
The aim of this work was to find an optimal setup for activity determination of Lu-177-based single photon emission computed tomography (SPECT) / computed tomography (CT) imaging reconstructed with two commercially available reconstructions (xSPECT Quant and Flash3D, Siemens Healthcare). For this purpose, 3D printed phantoms of different geometries were manufactured, different partial volume correction (PVC) methods were applied, and the accuracy of the activity determination was evaluated. METHODS: A 2-compartment kidney phantom (70% cortical and 30% medullary compartment), a sphere, and an ellipsoid of equal volumes were 3D printed, filled with Lu-177, and scanned with a SPECT/CT system...
November 2, 2017: Journal of Nuclear Medicine: Official Publication, Society of Nuclear Medicine
https://www.readbyqxmd.com/read/29097408/-18-f-fdg-pet-mri-in-chronic-sciatica-early-results-revealing-spinal-and-non-spinal-abnormalities
#18
Peter Cipriano, Daehyun Yoon, Harsh Gandhi, Dawn Holley, Dushyant Thakur, Ma Ith, Brian Hargreaves, David Kennedy, Matthew Smuck, Ivan Cheng, Sandip Biswal
Chronic sciatica is a major cause of disability worldwide, but accurate diagnosis of the offending pathology remains challenging. In this report, the feasibility of a fluorodeoxyglucose ((18)F-FDG) positron emission tomography/magnetic resonance imaging (PET/MRI) approach for improved diagnosis of chronic sciatica is presented. Methods:(18)F-FDG PET/MRI was performed on 9 chronic sciatica patients and 5 healthy volunteers. Region-of-interest analysis using maximum standardized uptake values (SUVmax) was performed, and (18)F-FDG uptake in lesions was compared with the corresponding areas in healthy controls...
November 2, 2017: Journal of Nuclear Medicine: Official Publication, Society of Nuclear Medicine
https://www.readbyqxmd.com/read/29097407/comparison-of-pet-ct-with-sequential-pet-mri-using-an-mr-compatible-mobile-pet-system
#19
Ryusuke Nakamoto, Yuji Nakamoto, Takayoshi Ishimori, Yasutaka Fushimi, Aki Kido, Kaori Togashi
Objectives: The current study tested a newly developed flexible PET (positron emission tomography) scanner prototype. This flexible PET (fxPET) system involves dual arc-shaped detectors based on silicon photomultipliers, which are designed to fit existing magnetic resonance (MR) devices, allowing us to get fused PET and MR images by sequential PET scanning. This prospective study sought to evaluate image quality, lesion detection rate, and quantitative values of fxPET in comparison with conventional whole-body (WB) PET images, and to assess the accuracy of registration...
November 2, 2017: Journal of Nuclear Medicine: Official Publication, Society of Nuclear Medicine
https://www.readbyqxmd.com/read/29084827/prospective-evaluation-of-68-ga-rm2-pet-mri-in-patients-with-biochemical-recurrence-of-prostate-cancer-and-negative-conventional-imaging
#20
Ryogo Minamimoto, Ida Sonni, Steven Hancock, Shreyas Vasanawala, Andreas Loening, Sanjiv Sam Gambhir, Andrei Iagaru
Purpose:(68)Ga-labeled DOTA-4-amino-1-carboxymethyl-piperidine-D-Phe-Gln-Trp-Ala-Val-Gly-His-Sta-Leu-NH2 ((68)Ga-RM2) is a synthetic bombesin receptor antagonist that targets gastrin-releasing peptide receptors (GRPr). GRPr proteins are highly overexpressed in several human tumors, including prostate cancer. We present data from the use of (68)Ga-RM2 in patients with biochemical recurrence (BCR) of prostate cancer (PC) and negative conventional imaging (CI). Methods: We enrolled 32 men with BCR PC, 59-83 year-old (mean±standard deviation (SD): 68...
October 30, 2017: Journal of Nuclear Medicine: Official Publication, Society of Nuclear Medicine
journal
journal
20164
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"